Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Mereo BioPharma Group Q3 2026 Results: Net Loss of $5.86M, Loss Narrows

Mereo BioPharma reported a net loss of $19.6 million for the nine months ended September 30, 2026, an improvement from the $34.5 million loss in the prior year period. Cash and cash equivalents decreased to $26.1 million from $41.0 million at the end of 2025, primarily driven by research and development expenses for its rare disease clinical programs.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.80.0
Profit before tax-5.9-7.0
Net income-5.9-7.0
EPS (diluted, $ a share)$-0.01$-0.01

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: MREO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Mereo BioPharma Group plc: key numbers

Share price
$0.2745Close, Nov 17
Market cap
$219M
Shares outstanding
798.5MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Mereo BioPharma Group plc

All →
8:11 AM ET 8-K
Financial Results

Mereo BioPharma Group Financial Results

Mereo BioPharma reported third quarter 2026 financial results and provided updates on its rare disease pipeline, including setrusumab for osteogenesis imperfecta and alvelestat for AATD-LD. The company ended the quarter with $26.1 million in cash, which is expected to fund operations into late-2027, excluding potential milestone payments from partners Ultragenyx and Sentynl Therapeutics.

“During the third quarter, we have made meaningful progress on our two core programs, setrusumab and alvelestat. These developments have the potential to set the stage for a transformational 2027 for Mereo, our shareholders and the patients we aim to serve.”

Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.